JP2024513231A - Ｅｒｔ２変異体及びその使用方法 - Google Patents

Ｅｒｔ２変異体及びその使用方法 Download PDF

Info

Publication number
JP2024513231A
JP2024513231A JP2023561275A JP2023561275A JP2024513231A JP 2024513231 A JP2024513231 A JP 2024513231A JP 2023561275 A JP2023561275 A JP 2023561275A JP 2023561275 A JP2023561275 A JP 2023561275A JP 2024513231 A JP2024513231 A JP 2024513231A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid substitution
optionally
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513231A5 (https=
Inventor
ミシェル エリザベス ハン
レベッカ テイラー コットマン
ラッセル モリソン ゴードリー
ゲイリー リー
ティモシー クアン－タ ルー
スリニヴァサラガヴァン カンナン
チャンドラ シェカール ヴァルマ
Original Assignee
センティ バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センティ バイオサイエンシズ インコーポレイテッド filed Critical センティ バイオサイエンシズ インコーポレイテッド
Publication of JP2024513231A publication Critical patent/JP2024513231A/ja
Publication of JP2024513231A5 publication Critical patent/JP2024513231A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023561275A 2021-04-06 2022-04-06 Ｅｒｔ２変異体及びその使用方法 Pending JP2024513231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171227P 2021-04-06 2021-04-06
US63/171,227 2021-04-06
PCT/US2022/023673 WO2022216823A1 (en) 2021-04-06 2022-04-06 Ert2 mutants and uses thereof

Publications (2)

Publication Number Publication Date
JP2024513231A true JP2024513231A (ja) 2024-03-22
JP2024513231A5 JP2024513231A5 (https=) 2025-03-21

Family

ID=83546546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561275A Pending JP2024513231A (ja) 2021-04-06 2022-04-06 Ｅｒｔ２変異体及びその使用方法

Country Status (9)

Country Link
US (1) US20240150433A1 (https=)
EP (1) EP4320228A4 (https=)
JP (1) JP2024513231A (https=)
KR (1) KR20240004433A (https=)
CN (1) CN117321192A (https=)
AU (1) AU2022255180A1 (https=)
CA (1) CA3213591A1 (https=)
IL (1) IL307269A (https=)
WO (1) WO2022216823A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121002054A (zh) * 2023-02-02 2025-11-21 森迪生物科学公司 改进的ert2突变体、诱导型细胞死亡系统及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157000A1 (en) * 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1397382B1 (en) * 2001-05-31 2008-08-06 Novartis AG Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
ES2439874T3 (es) * 2002-05-29 2014-01-27 Regeneron Pharmaceuticals, Inc. Sistema de expresión en eucariotas inducible
EP1680447A2 (en) * 2003-10-24 2006-07-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Orthogonal gene switches
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
KR102109820B1 (ko) * 2018-04-16 2020-05-12 한양대학교 산학협력단 비스페놀 a와의 결합력이 향상된 돌연변이 에스트로겐 수용체 단백질 및 이를 이용한 박테리아 균주

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157000A1 (en) * 2017-02-23 2018-08-30 Olema Pharmaceuticals, Inc. Compositions and methods for regulating immune system activity

Also Published As

Publication number Publication date
KR20240004433A (ko) 2024-01-11
IL307269A (en) 2023-11-01
WO2022216823A1 (en) 2022-10-13
CN117321192A (zh) 2023-12-29
AU2022255180A1 (en) 2023-11-16
EP4320228A4 (en) 2025-07-02
CA3213591A1 (en) 2022-10-13
EP4320228A1 (en) 2024-02-14
US20240150433A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
Liu et al. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
JP6625055B2 (ja) 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
JP2023546597A (ja) 部位特異的標的化エレメントによるプログラム可能な付加（ｐａｓｔｅ）を使用した部位特異的遺伝子操作のためのシステム、方法及び組成物
US20200263195A1 (en) Non-integrating dna vectors for the genetic modification of cells
US20220378822A1 (en) Combinatorial cancer immunotherapy
CN116917340A (zh) 诱导型细胞死亡系统
US20240226296A9 (en) Ert2 mutants and uses thereof
US20240182910A1 (en) Drug-regulatable transcription factors
US20260022364A1 (en) Ert2 mutants, inducible cell death systems, and uses thereof
US20240150433A1 (en) Ert2 mutants and uses thereof
US20240141364A1 (en) Drug-regulatable transcriptional repressors
CN117280037A (zh) 药物可调控的转录因子
TW202511491A (zh) 改良的多順反子系統及其用途
WO2025049866A1 (en) Engineered minimal core promoter and uses thereof
TW202421773A (zh) 用於光受體之細胞型特異性調控元件
TW202544250A (zh) 巨噬細胞特異性啟動子及其用途
EP4705323A1 (en) Modified degron polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260409